AU2008223446B2 - Restrictive agonist of Toll-like receptor 3 (TLR3) - Google Patents

Restrictive agonist of Toll-like receptor 3 (TLR3) Download PDF

Info

Publication number
AU2008223446B2
AU2008223446B2 AU2008223446A AU2008223446A AU2008223446B2 AU 2008223446 B2 AU2008223446 B2 AU 2008223446B2 AU 2008223446 A AU2008223446 A AU 2008223446A AU 2008223446 A AU2008223446 A AU 2008223446A AU 2008223446 B2 AU2008223446 B2 AU 2008223446B2
Authority
AU
Australia
Prior art keywords
virus
tlr3
poly
subject
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008223446A
Other languages
English (en)
Other versions
AU2008223446A1 (en
Inventor
Brian B. Gowen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Utah State University
Original Assignee
Utah State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Utah State University filed Critical Utah State University
Publication of AU2008223446A1 publication Critical patent/AU2008223446A1/en
Application granted granted Critical
Publication of AU2008223446B2 publication Critical patent/AU2008223446B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12211—Phlebovirus, e.g. Rift Valley fever virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2008223446A 2007-03-05 2008-03-05 Restrictive agonist of Toll-like receptor 3 (TLR3) Ceased AU2008223446B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90479207P 2007-03-05 2007-03-05
US60/904,792 2007-03-05
PCT/US2008/002874 WO2008109083A2 (en) 2007-03-05 2008-03-05 Restrictive agonist of toll-like receptor 3 (tlr3)

Publications (2)

Publication Number Publication Date
AU2008223446A1 AU2008223446A1 (en) 2008-09-12
AU2008223446B2 true AU2008223446B2 (en) 2012-02-02

Family

ID=39738981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008223446A Ceased AU2008223446B2 (en) 2007-03-05 2008-03-05 Restrictive agonist of Toll-like receptor 3 (TLR3)

Country Status (11)

Country Link
US (1) US20100183638A1 (enExample)
EP (1) EP2134172A4 (enExample)
JP (1) JP2010520284A (enExample)
KR (1) KR20090130019A (enExample)
CN (1) CN101652062A (enExample)
AU (1) AU2008223446B2 (enExample)
BR (1) BRPI0808637A2 (enExample)
CA (1) CA2680134A1 (enExample)
NZ (1) NZ579433A (enExample)
WO (1) WO2008109083A2 (enExample)
ZA (1) ZA200905954B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006322073A1 (en) 2005-12-07 2007-06-14 Hemispherx Biopharma, Inc. dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
AU2009215128A1 (en) * 2008-02-15 2009-08-20 Hemispherx Biopharma, Inc. Selective agonist of toll-like receptor 3
SI2340307T1 (sl) 2008-10-23 2016-02-29 Hemispherx Biopharma, Inc. Dvoverižne ribonukleinske kisline z robustno fizikalno-kemijsko strukturo in zelo specifično biološko aktivnostjo
US8722874B2 (en) 2008-10-23 2014-05-13 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US20100160413A1 (en) 2008-10-23 2010-06-24 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
HUE031756T2 (en) * 2008-10-31 2017-07-28 Janssen Biotech Inc TLR3 antagonists
WO2011072871A1 (en) * 2009-12-18 2011-06-23 Bavarian Nordic A/S Production of ifn-lambda by conventional dendritic cells and uses thereof
CN101780279B (zh) * 2009-12-22 2012-07-11 中山大学中山眼科中心 Toll-like receptor-3激动剂在制备促进伤口愈合的药物中的应用
WO2011130379A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
ES2620748T3 (es) * 2010-06-25 2017-06-29 Idera Pharmaceuticals, Inc. Nuevos agonistas del receptor de tipo toll 3 y procedimientos de su utilización
WO2015127002A1 (en) * 2014-02-19 2015-08-27 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
EP3321362A1 (en) 2016-11-10 2018-05-16 Centre Leon Berard Tlr3 agonist for use for inducing apoptosis in senescent cancer cells
MX2019007583A (es) * 2016-12-22 2019-09-04 Intervet Int Bv Vacuna de eimeria con una eficacia mejorada.
EP3833383A1 (en) 2018-08-06 2021-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers
WO2020232226A1 (en) 2019-05-16 2020-11-19 The Johns Hopkins University Compositions and methods for skin rejuvenation
US20240216364A1 (en) 2021-04-28 2024-07-04 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080726A (en) * 1985-08-12 2000-06-27 University Of Maryland Anti-viral and immuno stimulator polynucleotide duplex and use thereof
US5063209A (en) * 1985-08-26 1991-11-05 Hem Research, Inc. Modulation of aids virus-related events by double-stranded RNAs
US5683986A (en) * 1987-08-12 1997-11-04 Hemispherx Biopharma Inc. Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment
IE72103B1 (en) * 1987-08-12 1997-03-12 Hem Res Inc Promotion of host defense by systemic dsRNA treatment
AU3583797A (en) * 1996-06-28 1998-01-21 Regents Of The University Of California, The Enhancement of cancer cell death
GB0119346D0 (en) * 2001-08-08 2001-10-03 Bioclones Proprietary Ltd Process for the maturation of dendritic cells
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOWEN. B.B. et al. "Recombinant Eimeria Protozoan Protein Elicits Resistance to Acute Phlebovirus Infection in Mice but Not Hamsters" Antimicrobial Agents and Chemotherapy 2006, Vol. 50, No. 6, pages 2023-2029 *
HUBBELL. H. R. et al. "Antitumor Effects of Interleukin-2 and Mismatched Double-Stranded RNA, Individually and in Combination, against a Human Malignant Melanoma Xenograft. Cancer Immunology lmmunotherapy 1992, Vol 35, pages 151-157 *

Also Published As

Publication number Publication date
BRPI0808637A2 (pt) 2014-08-05
JP2010520284A (ja) 2010-06-10
WO2008109083A2 (en) 2008-09-12
CA2680134A1 (en) 2008-09-12
WO2008109083A3 (en) 2008-11-27
ZA200905954B (en) 2011-10-26
EP2134172A2 (en) 2009-12-23
NZ579433A (en) 2012-05-25
US20100183638A1 (en) 2010-07-22
EP2134172A4 (en) 2011-06-01
CN101652062A (zh) 2010-02-17
KR20090130019A (ko) 2009-12-17
AU2008223446A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
AU2008223446B2 (en) Restrictive agonist of Toll-like receptor 3 (TLR3)
Krieg Antiinfective applications of toll-like receptor 9 agonists
US20210322545A1 (en) Smc combination therapy for the treatment of cancer
CN107412260B (zh) cGAS-STING通路激活剂及其用途
Nichani et al. In vivo immunostimulatory effects of CpG oligodeoxynucleotide in cattle and sheep
Gill et al. The role of toll‐like receptor ligands/agonists in protection against genital HSV‐2 infection
CN117050986B (zh) 具有免疫刺激活性的CpG寡聚核苷酸及其用途
US20100310600A1 (en) Selective agonist of toll-like receptor 3
CA2632516C (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
Logue et al. Treatment with cationic liposome–DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge
ES2702618B2 (es) Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica.
Li et al. Prophylactic, therapeutic and immune enhancement effect of liposome‐encapsulated PolyICLC on highly pathogenic H5N1 influenza infection
Gaajetaan et al. The type I interferon response during viral infections: a “SWOT” analysis
WO2022192655A1 (en) Polysaccharide adjuvants for virus vaccines
US7550150B2 (en) Methods of treating or preventing a disease, disorder or condition associated with a viral infection
Deanasa et al. The potential of antisense oligonucleotides (ASO) through inhalation based on gold nanoparticle (AuNP) delivery system in inhibiting SARS-CoV-2 replication and transcription
Yang et al. Innate defense regulator peptide synergizes with CpG ODN for enhanced innate intestinal immune responses in neonate piglets
HK1136158A (en) Restrictive agonist of toll-like receptor 3 (tlr3)
Castillo et al. Myeloid Cell Reservoirs: Role in HIV-Host Interplay and Strategies for Myeloid Reservoir Elimination
KR101293363B1 (ko) 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물
Mitchell TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly (I: C12U), but not Poly (I: C): differential recognition of synthetic dsRNA molecules
Nainwani et al. Macrophage Targeting for Therapy of HIV
Saidoune et al. Skin manifestations of SARS-CoV-2 infection and its vaccination
AU2013206335B2 (en) dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
WO2013007703A1 (en) CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired